Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb’s Opdivo shows benefits in treatment of melanoma

Bristol-Myers Squibb’s Opdivo shows benefits in treatment of melanoma

7th July 2017

Bristol-Myers Squibb has reported the findings of a new clinical trial that demonstrate the benefits its drug Opdivo can offer to melanoma patients.

Data from the CheckMate-238 phase III trial have shown that Opdivo was able to deliver a better performance in patients with stage IIIb/c or stage IV melanoma who were at high risk of recurrence following complete surgical resection than the company's older drug Yervoy.

Opdivo met its primary endpoint at a planned interim analysis by demonstrating superior recurrence-free survival rates in patients compared to Yervoy, with data from this study to be submitted for presentation at an upcoming medical conference.

Presently, there remains an unmet need for additional options for this condition, as the majority of stage III and resected stage IV high-risk melanoma patients experience disease recurrence after surgery.

Dr Vicki Goodman, development lead for melanoma and genitourinary cancers at Bristol-Myers Squibb, said: "We are committed to researching therapies that may better meet the needs of this patient population and look forward to sharing these data with health authorities soon."

The drug was approved by the European Commission as a treatment for urothelial carcinoma last month.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837670-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.